Fr. 117.00

Prostate Cancer Prevention

English · Paperback / Softback

Shipping usually within 6 to 7 weeks

Description

Read more

Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5 -reductase inhibitors, DFMO and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.

List of contents

Biology and natural history of prostate cancer.- Nutrition and prostate cancer.- Prostate cancer chemoprevention.- Lifestyle and dietary factors.- GWAS in prostate cancer predisposition and application to screening and prevention.- Risk prediction biomarkers - CCP.- Risk prediction biomarkers - TMPRSS2-ERG.- Risk prediction biomarkers - PCA3.- Risk adapted chemoprevention for PCa.- Outlook for 5 reductase inhibitors in prostate cancer prevention.- Prostate cancer chemoprevention: Aspirin.- Prostate cancer chemoprevention: DFMO.- Prostate cancer chemoprevention: Lycopene.- Distinguishing aggressive from indolent prostate cancer.- Prognosis and Management of low grade disease - Management of Gleason 6.- Prostate cancer prevention: Policy & Research implications.

Summary

Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5α-reductase inhibitors, DFMO and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.

Additional text

From the reviews:
“Part of the Recent Advances in Cancer Research series, this book’s title suggests that it tackles prevention of prostate cancer. … scientists and clinicians who deal with prostate cancer are the main audience. … The discussion of agent development and strategies is very useful to anyone looking to tackle the challenging area of prostate cancer chemoprevention.” (Leonard G. Gomella, Doody’s Book Reviews, May, 2014)

Report

From the reviews:
"Part of the Recent Advances in Cancer Research series, this book's title suggests that it tackles prevention of prostate cancer. ... scientists and clinicians who deal with prostate cancer are the main audience. ... The discussion of agent development and strategies is very useful to anyone looking to tackle the challenging area of prostate cancer chemoprevention." (Leonard G. Gomella, Doody's Book Reviews, May, 2014)

Product details

Assisted by A Thorat (Editor), A Thorat (Editor), Jac Cuzick (Editor), Jack Cuzick (Editor), Mangesh Thorat (Editor), Mangesh A. Thorat (Editor)
Publisher Springer, Berlin
 
Languages English
Product format Paperback / Softback
Released 01.01.2016
 
EAN 9783662524435
ISBN 978-3-662-52443-5
No. of pages 169
Dimensions 155 mm x 10 mm x 235 mm
Weight 283 g
Illustrations VIII, 169 p. 11 illus., 4 illus. in color.
Series Recent Results in Cancer Research
Recent Results in Cancer Research
Subjects Natural sciences, medicine, IT, technology > Medicine > Clinical medicine

B, Medicine, INTERNAL MEDICINE, Oncology, Urology, Cancer Research, Biomedical Research, Urology & urogenital medicine

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.